Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Vt-1161
1. 1340593-59-0
2. Vt-1161
3. Oteseconazole [usan]
4. Vhh774w97n
5. Chembl3311228
6. (2r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
7. (r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1h-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol
8. 2-pyridineethanol, Alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphar)-
9. 2-pyridineethanol, Alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-, (alphar)-
10. Vivjoa
11. Oteseconazole [inn]
12. Oteseconazole (usan/inn)
13. Unii-vhh774w97n
14. Oteseconazole, (+)-
15. Oteseconazole [who-dd]
16. Schembl17113021
17. Chebi:188153
18. Bdbm50046187
19. Who 10138
20. Db13055
21. Sb17420
22. Vt-1161vt-1161
23. Hy-17643
24. Cs-0016914
25. D11785
26. D87154
27. Q27291837
28. (2r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1h-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol
29. (alphar)-alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridineethanol
| Molecular Weight | 527.4 g/mol |
|---|---|
| Molecular Formula | C23H16F7N5O2 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 8 |
| Exact Mass | 527.11922190 g/mol |
| Monoisotopic Mass | 527.11922190 g/mol |
| Topological Polar Surface Area | 86 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 743 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of vulvovaginal candidiasis
J - Antiinfectives for systemic use
J02 - Antimycotics for systemic use
J02A - Antimycotics for systemic use
J02AC - Triazole and tetrazole derivatives
J02AC06 - Oteseconazole
API SUPPLIERS
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
NDC Package Code : 10745-1323
Start Marketing Date : 2019-08-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...
About the Company : Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu Province, China. The company was fou...
About the Company : Wuhan Sun-shine chemical Corporation Limited (Shanghai Sun-shine Chemical Technology Corporation Limited) is a high-tech enterprise engaged inR&D and sales of related compounds of ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Vivjoa (oteseconazole) is a selective and orally bioavailable CYP51 inhibitor antifungal, which is approved in China for the treatment of severe vulvovaginal candidiasis.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Mycovia Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Mycovia Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Mycovia Announces VIVJOA® Launch for Severe Vulvovaginal Candidiasis in China
Details : Vivjoa (oteseconazole) is a selective and orally bioavailable CYP51 inhibitor antifungal, which is approved in China for the treatment of severe vulvovaginal candidiasis.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 07, 2024
Details:
VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Jiangsu Hengrui Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Jiangsu Hengrui Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2023
Details:
VIVJOA (oteseconazole) was statistically superior to placebo in preventing recurrence of infection in women with RVVC and noninferior to fluconazole in treating acute VVC in women with RVVC.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VIVJOA (oteseconazole) was statistically superior to placebo in preventing recurrence of infection in women with RVVC and noninferior to fluconazole in treating acute VVC in women with RVVC.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2022
Details:
Of the 71 VIVJOA (oteseconazole) treated participants in the observational extension study, 85% completed 96 weeks without a recurrent VVC episode, where they had experienced at least three episodes in the year prior to study entry.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Of the 71 VIVJOA (oteseconazole) treated participants in the observational extension study, 85% completed 96 weeks without a recurrent VVC episode, where they had experienced at least three episodes in the year prior to study entry.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2022
Details:
Two global VIOLET Phase 3 studies met primary and key secondary endpoints, with authors concluding VIVJOA (oteseconazole) is highly efficacious in preventing recurrence of VVC through 48 weeks in participants with a history of RVVC.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Two global VIOLET Phase 3 studies met primary and key secondary endpoints, with authors concluding VIVJOA (oteseconazole) is highly efficacious in preventing recurrence of VVC through 48 weeks in participants with a history of RVVC.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Details:
VIVJOAâ„¢ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VIVJOAâ„¢ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 18, 2022
Details:
85% of patients who took a 12-week course of Vivjoa (oteseconazole) completed 96 weeks without a recurrent VVC episode, with an average time of 92 weeks without recurrence.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 85% of patients who took a 12-week course of Vivjoa (oteseconazole) completed 96 weeks without a recurrent VVC episode, with an average time of 92 weeks without recurrence.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2022
Details:
Approval of VIVJOAâ„¢ marks a significant therapeutic advancement for reducing the incidence of RVVC, a condition with substantial unmet need, in permanently infertile and postmenopausal women.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vivjoa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Approval of VIVJOAâ„¢ marks a significant therapeutic advancement for reducing the incidence of RVVC, a condition with substantial unmet need, in permanently infertile and postmenopausal women.
Brand Name : Vivjoa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2022
Details:
Oteseconazole (VT-1161) is a novel, oral therapy for RVVC that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy for treatment of recurrent vulvovaginal candidiasis (RVVC).
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: VT-1161
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Oteseconazole (VT-1161) is a novel, oral therapy for RVVC that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy for treatment of recurrent vulvovaginal candidiasis (RVVC).
Brand Name : VT-1161
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2021
Details:
Oteseconazole’s clinical development plan was comprised of three trials – two global VIOLET studies and one U.S.-focused ultraVIOLET study, including more than 870 patients at 232 sites across 11 countries.
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: VT-1161
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Oteseconazole’s clinical development plan was comprised of three trials – two global VIOLET studies and one U.S.-focused ultraVIOLET study, including more than 870 patients at 232 sites across 11 countries.
Brand Name : VT-1161
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2033-05-09
US Patent Number : 11247981
Drug Substance Claim :
Drug Product Claim :
Application Number : 215888
Patent Use Code : U-3366
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-09
Patent Expiration Date : 2031-04-22
US Patent Number : 8754227
Drug Substance Claim :
Drug Product Claim :
Application Number : 215888
Patent Use Code : U-3366
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-04-22
Patent Expiration Date : 2031-04-22
US Patent Number : 8236962
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 215888
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-04-22
Patent Expiration Date : 2036-03-17
US Patent Number : 9840492
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 215888
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-03-17
Patent Expiration Date : 2036-03-17
US Patent Number : 10414751
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 215888
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-03-17
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
